Serono

Serono was a biotechnology company founded in 1977 and headquartered in Geneva, Switzerland. It was a significant player in the biopharmaceutical industry, focusing on the development and marketing of treatments for various diseases. The company was particularly known for its work in areas such as fertility, neurology, and growth disorders.

One of Serono's most successful products was Gonal-f, a recombinant follicle-stimulating hormone used in assisted reproductive technologies. Another notable product was Rebif, a disease-modifying therapy for multiple sclerosis. The company also developed and marketed Serostim, a recombinant human growth hormone for treating growth failure in children and adults.

Serono was a publicly traded company for many years, listed on stock exchanges in Europe and the United States. In 2007, Serono was acquired by the German pharmaceutical company Merck KGaA. Following the acquisition, Serono became the biopharmaceutical division of Merck KGaA, operating under the name EMD Serono in the United States and Canada, and Merck Serono in other regions. This integration aimed to leverage the combined strengths of both companies in research, development, and market reach. The legacy of Serono continues within Merck KGaA's biopharmaceutical operations.